publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
In this study, as a bioisosteric alternative scaffold of the antiviral aryl diketoacids (ADKs), we used 5hydroxychromone on which two arylmethyloxy substituents were installed. The 5-hydroxychromones (5be5g) thus prepared showed anti-HCV activity and, depending on the aromatic substituents on the 2-arylmethyloxy moiety, some of the derivatives (5be5f) were also active against SCV. In addition, unlike the ADKs which showed selective inhibition against the helicase activity of the SCV NTPase/helicase, the 5-hydroxychromones (5be5f) were active against both NTPase and helicase activities of the target enzyme. Among those, 3-iodobenzyloxy-substituted derivative 5e showed the most potent activity against HCV (EC 50 ¼ 4 mM) as well as SCV (IC 50 ¼ 4 mM for ATPase activity, 11 mM for helicase activity) and this might be used as a platform structure for future development of the multi-target or broad-spectrum antivirals.
Ó 2011 Elsevier Masson SAS. All rights reserved.
Introduction
Aryl diketoacid (ADK) has previously been identified to inhibit HIV-1 (human immunodeficiency virus) integrase [1] and RNAdependent RNA polymerase (RdRp) of hepatitis C virus (HCV) [2, 3] . In our previous communications, we reported the ADKs with an arylmethyloxy or arylmethylamino substituent attached at the 2-, 3-, or 4-position of an aromatic ring (1, Fig. 1 ) as inhibitors of the HCV RdRp activity [4] as well as NTPase/helicase activity of SARSassociated coronavirus (SARS-CoV, SCV) [5] . Inhibition of the two different viral enzymes, HCV RdRp and SCV NTPase/helicase, by the same class of compounds was noteworthy because novel multitarget or broad-spectrum antivirals might be developed from this structure. Later, in order to improve unfavorable physicochemical as well as pharmacokinetic properties associated with the diketoacid moiety [6] , bioisosteric replacement of pharmacophoric diketoacid core structure (thick line in 1, Fig. 1 ) with a b-hydroxyketone moiety (thick line in 2, Fig. 1 ) of 5-hydroxyflavone scaffold was attempted. Compared with the ADKs, the 5-hydroxyflavone scaffold provides additional advantage because both sides of the central b-hydroxyketone moiety can be substituted (R 1 eR 3 in 2, Fig. 1 ) to allow extensive structureeactivity relationship study. In our recent proof-of-concept study, the key pharmacophoric arylmethyloxy group of the antiviral ADKs was introduced on opposite sides (3-and 7-positions) of the 5-hydroxyflavone core structure to give the corresponding galangin derivatives, 3-O-arylmethyloxygalangins (3) [7] and 7-O-arylmethyloxygalangins (4) [8] , and significant anti-HCV activities were observed from both derivatives. However, unlike the ADKs with arylmethyloxy substituents (1) which showed inhibitory activity against both HCV RdRp and SCV NTPase/helicase, the galangin derivatives (3 and 4) lacked anti-SCV activity [9] . This result suggests that the HCV RdRp might have a binding site specific for the 5-hydroxyflavone scaffold around which two hydrophobic sites with similar shapes are located. It can also be assumed that the SCV NTPase/helicase might not be able to accommodate a 2-phenyl group of the galangin scaffold. Thus, in order to confirm this rationale, we intended to use 5-hydroxychromone instead of 5-hydroxyflavone as a platform structure on which two arylmethyloxy substituents were attached at the same time (5 0 , Fig. 1 ). However, due to synthetic difficulties associated with synthesis of 5 0 , we flipped a core AC ring system of the chromone scaffold and introduced the substituents on both 2-and 6-positions. As an enoleketo arrangement on a flat fused AC ring system forming an intramolecular hydrogen bond is believed as a key pharmacophoric element of the flavones as well as the chromones, it was fair to assume that flipping the AC ring system to a ketoeenol form (CA ring system) would not affect the pharmacophore of the chromone scaffold. As shown in Fig. 1 , the 2,6-bis-O-arylmethyloxy substituents attached to the flipped fused ring system in 5 are superimposable to those at the 3-and 7-positions of 5 0 . The arylmethyloxy substituent at 6-position was fixed with a 3-chlorobenzyloxy group because it provided the 3-O-arylmethyloxygalangin derivatives (3) with the most potent inhibitory activity against the HCV RdRp (IC 50 ¼ 0.1 mM) [7] . In contrast, as the anti-HCV activity of the 7-Oarylmethylgalangin derivatives (4) was found to be critically dependent upon size and position of a hydrophobic aromatic substituent in the arylmethyloxy group [8] , the aromatic substituent of the 2-arylmethyloxy group was varied with Cl-, I-, and CN-at 3-, 4-, and 5-positions of the aromatic ring. Herein we report synthesis and evaluation of anti-HCV as well as anti-SCV activity of novel 2-arylmethyloxy-6-(3-chlorobenzyloxy)-5hydroxychromones 5 (Fig. 1 ).
Results and discussion

Chemistry
Synthesis of the title compounds, 2-arylmethyloxy-6-(3chlorobenzyloxy)-5-hydroxychromone (5ae5g) is summarized in Scheme 1.
Following literature methods [10] , 2,5-dihydroxy-6methoxyacetophenone (6) was prepared from commercially available 2,5-dihydroxyacetophenone. Due to intramolecular hydrogen bonding, the 5-OH group of 6 selectively reacted with 3-ClPhCH 2 Br in the presence of K 2 CO 3 to provide the alkylated product 7 in 58% yield. Treatment of 7 with LiHMDS, CS 2 , and MeI in THF provided the corresponding ketene dithioacetal, which was then cyclized under basic conditions to give 2-methylthiochromone 8 in 51% yield [11] . The sulfide 8 was oxidized by mCPBA to 9, whose methylsulfonyl group was then successfully displaced with sodium salt of variously substituted benzyl alcohols to furnish 2,6-bis-arylmethyloxy-5hydroxychromone derivatives (10ae10g) in 47e71% yield [12] . Final Lewis acid-mediated demethylation of 10 to 5 necessitated careful control of the reaction conditions because of concurrent loss of the arylmethyl moiety. Thus, after optimization of Lewis acid as well as the reaction conditions, use of less than one equivalent (w0.89) of AlCl 3 in CH 2 Cl 2 was found to be the method of choice to provide the desired 2-arylmethyloxy-6-(3-chlorobenzyloxy)-5hydroxychromones (5ae5g) in moderate (43e57%) yield.
Biological activity
In this study, we combined the pharmacophoric arylmethyloxy group of 3-O-arylmethylgalangins (3) and 7-O-arylmethylgalangins (4) on the 5-hydroxychromone scaffold to prepare 7 derivatives of 2,6-bis-arylmethyloxy-5-hydroxychromones (5ae5g). The synthesized 5-hydroxychromone derivatives were then evaluated for their antiviral activity against HCV as well as SCV, and the result is summarized in Table 1 .
Anti-HCV activity
While the 5-hydroxychromone derivatives 5be5g with arylmethyloxy substituents at both 2-and 6-positions showed moderate to potent anti-HCV activity, the compound 5a with 2benzyloxy substituent (R ¼ H) did not show any anti-HCV activity. More interestingly, compounds with the same type of substituent (5b/5c and 5e/5f) showed similar anti-HCV activity regardless of the position of substitution. In particular, derivatives with bulky iodo substituents (5e and 5f, EC 50 ¼ 3e4 mM) were significantly more active than the chlorine-(5b and 5c,
In line with these observations, it is noteworthy that the 3,5-dichloro-substituted derivative 5d showed the most potent anti-HCV activity (EC 50 ¼ 1 mM), which is comparable to that of the ADK (1, EC 50 ¼ 0.8 mM). Taken together, these results indicate the critical role of the aromatic substituents in binding of the 5hydroxychromone derivatives to the viral target protein and propose a large hydrophobic binding site in the viral target protein accommodating an aromatic ring with bulky substituents.
As the HCV RdRp was proven to be a viral target enzyme of ADKs [2e4], it was also assumed as a potential viral target protein of the bioisosteres of ADKs including flavone as well as chromone derivatives. Inhibitory activity of the synthesized 5hydroxychromone derivatives (5ae5g) against HCV genotype 1b NS5B Dc21 enzyme was estimated [13] , but the enzyme activity was not affected by addition of the test compounds (data not shown). Thus, the anti-HCV replicon activity of the 5hydroxychromone derivatives could be attributed to a different mechanism yet to be determined.
Anti-SCV activity
Viral helicases couple energy from nucleotide triphosphate (NTP) hydrolysis with unwinding of duplex viral nucleic acid and, due to a critical role in viral viability, both NTPase and duplex unwinding activity have been the subjects of antiviral drug discovery campaigns [14, 15] . In our previous study, we have identified ADKs (1) as anti-SCV agents with selective inhibition (IC 50 ¼ 5.4e13.6 mM) against duplex DNA-unwinding helicase activity of SCV NTPase/helicase without significant impact on the ATPase activity (1, Table 1) [5] . Unfortunately, presumably due to the presence of additional 2-phenyl group, neither of the two 5hydroxyflavone derivatives (3 and 4) showed anti-SCV activity (Table 1) . Thus, in this study, the 5-hydroxyflavone scaffold was replaced with a 5-hydroxychromone, on which two arylmethyloxy substituents were installed. The resulting derivatives 5ae5g showed interesting structureeactivity relationship. First, in comparison with the ADKs which showed selective inhibition against the helicase activity, 5-hydroxy-6-(3-chlorobenzyloxy)chromone derivatives with chloro-(5b and 5c) or iodo-(5e and 5f) benzyloxy substituent inhibited both NTPase and helicase activities with more potent inhibition against NTPase activity (Table 1) . Second, unlike the anti-HCV activity, inhibitory activity against SCV NTPase/helicase was dependent upon the position of the aromatic substituent, and the 3-substituted derivatives (5b and 5e) showed significantly more potent activity compared with the corresponding 4-substituted congeners (5c and 5f) (Table 1) . Third, 3,5-dichloro-substituted derivative 5d, which showed the most potent anti-HCV activity among the series, was not effective in inhibiting the SCV NTPase/helicase (IC 50 > 50 mM). Fourth, among the anti-SCV 5-hydroxychromones, 3-iodo-substituted one (5e) showed the most potent activity (IC 50 ¼ 4 mM for ATPase activity, 11 mM for helicase activity). Based on these results, it might be concluded that the SCV NTPase/helicase has a hydrophobic binding region specific Table 1 Anti-HCV activity, inhibition of the SCV NTPase/helicase, and cytotoxicity of the 2-arylmethyloxy-6-(3-chlorobenzyloxy)-5-hydroxychromones (5ae5g) in comparison with those of the ADK (1), 3-O-arylmethylgalangin (3), and 7-O-arylmethylgalangin (4). for 3-substituted aromatic rings attached to the 6-(3chlorobenzyloxy)-5-hydroxychromone core structure.
Compds
Cytotoxicity
The 5-hydroxychromone derivatives (5ae5g) showed no cytostatic effect in human normal fibroblast cell line HS27 up to 50 mM (Table 1) .
Conclusion
Structureeactivity relationship study of the ADKs and the 5-hydroxyflavones proposed that the 5-hydroxychromone derivatives with two arylmethyloxy substituents would show antiviral activity against both HCV and SCV. 2-Arylmethyloxy-6-(3chlorobenzyloxy)-5-hydroxychromones (5be5g), thus prepared, showed anti-HCV activity in cell-based assay. As anticipated, depending on the aromatic substituents on the 2-arylmethyloxy moiety, some of the derivatives (5be5f) were also active against SCV. In addition, unlike the ADKs which showed selective inhibition against the helicase activity of the SCV NTPase/helicase, 2arylmethyloxy-6-(3-chlorobenzyloxy)-5-hydroxychromones (5be5f) were active against both NTPase and helicase activities of the target enzyme. Among those, 2-(3-iodobenzyloxy)-6-(3chlorobenzyloxy)-5-hydroxychromone (5e) showed the most potent activity against HCV (EC 50 ¼ 4 mM) as well as SCV (IC 50 ¼ 4 mM for ATPase activity, 11 mM for helicase activity). In the absence of structural information of the SCV NTPase/helicase, this result would provide valuable information for designing more potent inhibitors. Also, the antiviral agents active both against HCV and SCV discovered in this study might be used as a platform structure for future development of the multi-target or broad-spectrum antivirals.
Experimental
Chemistry
General remarks
Nuclear magnetic resonance spectra were recorded at 400 MHz for 1 H NMR and at 100 MHz for 13 C NMR with tetramethylsilane as the internal standard. Chemical shift are reported as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), or br s (broad singlet). Coupling constants are reported in hertz (Hz). The chemical shifts are reported as parts per million (d) relative to the solvent peak. All tested compounds were !95% purity as determined by reverse phase HPLC. HPLC was performed on equipment with variable wavelength (VW) UV detector and C18 e A 250 Â 4.6 mm column. Analytical conditions were as follows: Gradient used was 20%e60% acetonitrile in water containing 0.1% formic acid (0e3 min), 60%e80% acetonitrile in water containing 0.1% formic acid (3e5 min), 80%e100% acetonitrile in water containing 0.1% formic acid (5e7 min), 100% acetonitrile in water containing 0.1% formic acid (7e15 min), 100%e60% acetonitrile in water containing 0.1% formic acid (15e17 min), 60%e20% acetonitrile in water containing 0.1% formic acid (17e20 min). Flow rate was set to 1 mL/min. UV was detected at two different wavelengths (340 nm and 220 nm).
Synthesis of 1-[3-(3-chloro-benzyloxy)-6-hydroxy-2methoxy-phenyl]-ethanone (7)
To a solution of 6 (500 mg, 2.74 mmol) and K 2 CO 3 (379 mg, 2.74 mmol) in acetone (20 mL) was slowly added (1bromomethyl)-3-chlorobenzene (0.32 mL, 2.47 mmol). The reaction mixture was stirred for 2 h at 60 C and then cooled to room temperature, filtered with acetone, and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel (Hex:EtOAc The compound 7 (800 mg, 2.61 mmol) obtained above was dissolved in THF (5 mL) and the resulting solution was added to a stirred solution of 1M LiHMDS (7.83 mL, 7.83 mmol) in THF (15 mL) over 10 min at À78 C. After 30 min, CS 2 (0.24 mL, 3.92 mmol) was added in one portion, and the reaction mixture was allowed to warm to 0 C. After 1 h, MeI (0.36 mL, 5.74 mmol) was added dropwise over 10 min, and stirring was continued for additional 1 h at room temperature. A solution of aq. 10N KOH (10 mL) was added and the reaction mixture was stirred at 60 C for 30 min. The reaction mixture was allowed to cool to 0 C and quenched by addition of 1N HCl. After phase separation, the aqueous phase was extracted with CH 2 Cl 2 three times, and the combined organic layers were dried over MgSO 4 and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel (Hex:EtOAc To a stirred solution of 8 (500 mg, 1.38 mmol) in CH 2 Cl 2 (20 mL) was added mCPBA (681 mg, 3.04 mmol) at 0 C. The reaction mixture was stirred for 12 h at room temperature, and then washed with saturated aq. NaHCO 3 solution, dried over MgSO 4 , and concentrated under reduced pressure. The resulting crude product was purified by column chromatography on silica gel (Hex:EtOAc ¼ 2:1) to afford 9 (387 mg, 0.98 mmol, 71% yield) as off- 
Synthesis of 2-arylmethyloxy-6-(3-chloro-benzyloxy)-5methoxy-chromen-4-one (10)
The procedure described below for the synthesis of 10a is representative: To a solution of 9 (200 mg, 0.51 mmol) in THF (12 mL) was added NaH (41 mg, 1.02 mmol) and BnOH (0.06 mL, 0.61 mmol) at 0 C, and the mixture was stirred for 6 h at room temperature. The reaction was quenched with 1N HCl and extracted with CH 2 Cl 2 . The combined organic layers was dried over MgSO 4 and concentrated under reduced pressure. The crude compound was purified by column chromatography on silica gel (Hex:EtOAc ¼ 3:2) to afford 10a (106 mg, 0.25 mmol, 49% yield) as white powder. Reaction of 10f (318 mg, 0.58 mmol) with AlCl 3 (68 mg, 0.52 mmol) according to the procedure described above for the synthesis of 5a afforded 5f (132 mg, 0.25 mmol, 43% yield) as white 
Biological assay
Anti-HCV assay
The human hepatoma cell line Huh-7, carrying the subgenomic HCV genotype 1 replicon with the luc-ubi-neo (reporter/selective) fusion gene, was kindly provided by Dr. Ralf Bartenschlager (University of Heidelberg, Heidelberg, Germany) [16] . Huh-5-2 cells were seeded at a density of 5 Â 10 3 per well in a tissue culturetreated white 96-well view plate in complete DMEM supplemented with 500 mg/mL G418. After incubation for 24 h at 37 C (5% CO 2 ), medium was refreshed (with G418) and DMSO stock of test compounds was added. After 4 days of incubation at 37 C, cell culture medium was removed and luciferase activity was determined using the Steady-Glo luciferase assay system (Promega, Leiden, The Netherlands).
Anti-SCV assay
Carboxytetramethylrhodamine (TAMRA)-modified 45-baseoligomer and fluorescein-modified 25-base-oligomer were purchased from Integrated DNA Technologies: 
Cell viability assay
Normal human fibroblast cells (HS27) were seeded (5 Â 10 3 cells/well) in tissue-cultured COSTAR clear bottom 96-well plate in complete DMEM (Dulbecco's Modified Eagle Media) and incubated for 1 day (37 C, 5% CO 2 ). Prepared test compounds dissolved in DMSO were diluted into 6 different concentrations (0.1, 0.5, 1, 5, 10, 50 mM) and added to the media. After 24 h, cell viability was estimated by MTT assay. Each experiment was performed in triplicates and repeated three times.
